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Abstract Cytokine receptor signaling involves the Jak/Stat
pathways. Heterotrimeric IL-2R (K, L, Qc chains) activates Jak1
and Jak3, whereas homodimeric PRLR activates Jak2. The
requirements directing such specificity of Jak activation are
unknown. We show that chimeric receptors containing the
intracellular domain of IL-2RL chain fused to the extracellular
domain of either EPOR or Kit, a non-cytokine receptor, activate
Jak2. This observation provides evidence that IL-2RL intrinsi-
cally possesses the ability to activate Jak2, but that this property
is only displayed in homodimerized complexes. Our data suggest
a role for the stoichiometry of cytokine receptors in selective
activation of Janus kinases.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The stoichiometry of activated cytokine receptor complexes
is highly variable. For instance, PRLR and EPOR are homo-
dimers, IL-2R is a heterotrimeric complex involving K, L and
Qc chains, whereas signaling IL-6R is a hexameric complex
consisting of two molecules each of IL-6, IL-6R (K chain)
and gp130 [1]. Cytokine receptors are intrinsically devoid of
any enzymatic activity and signal through the Jak/Stat cas-
cade [2]. To date, four Jak kinases (Jak1, Jak2, Jak3, Tyk2)
and seven Stats (Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b,
Stat6) have been identi¢ed. Although it is widely assumed
that the speci¢city of cytokine receptor signaling is partly
directed by the subset of Jaks and Stats that are activated
by each receptor, the molecular basis of such speci¢city is
not yet completely understood. Based on mutational studies
of tyrosines within several cytokine receptors, it has been
suggested that ¢rst the receptor-Stat interaction involves
phosphotyrosines of the former and the SH2 domain of the
latter, and second the panel of Stats that are speci¢cally re-
cruited by receptors is directed by consensus sequences in the
near environment of these phosphotyrosines [3^6]. Although it
is clear that the associated Jaks interact with the membrane-
proximal part of the receptor cytoplasmic domains, which
involves the proline-rich box 1 [2,7], the molecular features
directing the speci¢c recruitment of a given Janus kinase by
a given receptor are still unknown. Homodimeric receptors
for PRL, EPO or GH recruit Jak2 [8^10], whereas heterotri-
meric IL-2R selectively recruits Jak1 and Jak3 through its L
and Qc subunits, respectively [11,12]. In a recent study [13],
however, we have shown that a chimeric receptor composed
of the extracellular domain of the PRLR fused to the cyto-
plasmic domain of the IL-2RL chain (so-called PRLR/2L) is
able to activate both Jak1 and Jak2, despite the fact that the
kinase associated with the IL-2RL chain within the wild type
IL-2R is Jak1. This observation provided evidence that the
type of Jak naturally activated by IL-2RL does not exclusively
depend, if at all, on intrinsic sequences within its cytoplasmic
domain. In view of this unexpected observation, we addressed
the question whether the extracellular domain of PRLR per se
or, alternatively, the homodimeric stoichiometry of the acti-
vated PRLR/2L chimeric receptor might participate in direct-
ing activation of Jak2. To test these hypotheses, we have
analyzed the signaling properties of two other chimeric recep-
tors, both containing the cytoplasmic domain of the IL-2RL
chain linked to the extracellular domain either of the EPOR
(so-called EPOR/2L chimera) or of the receptor tyrosine kin-
ase Kit (so-called Kit/2L chimera; Fig. 1). Our results show
that homodimerization of IL-2RL is necessary and su⁄cient
to activate Jak2 and downstream signaling pathways.
2. Materials and methods
2.1. Materials
Ovine PRL (NIAMDD) was obtained from the National Hormone
and Pituitary Program/NIDDK (Baltimore, MD, USA). SCF was a
generous gift from Genzyme (Cambridge, MA, USA) and recombi-
nant human EPO from Dr. P. Mayeux (Paris, France). The following
antibodies were obtained from commercial sources: anti-phosphotyr-
osine (4G10) and anti-Jak2 (Upstate Biotechnology), rabbit polyclo-
nal anti-Stat5a/Stat5b (Santa Cruz Biotechnology), rat monoclonal
anti-Kit extracellular domain (ACK-2) and £uorescein-conjugated
anti-rat IgG antibody (Gibco-BRL). Other reagents were obtained
from commercial sources as previously described [13].
2.2. Expression vectors
An EcoRI/EcoRV cDNA fragment encoding the murine EPOR
extracellular domain [14] was obtained by PCR and substituted for
that encoding the PRLR extracellular domain in the pECE-PRLR/2L
expression vector [13]. Kit/2L, cloned into the eukaryotic expression
vector pHLAPr-1-neo [15], has been previously described [16].
2.3. Cell culture and stable transfection
CHO K1 cells were routinely cultured as described [13]. CHO cells
stably expressing EPOR/2L or Kit/2L chimeras were selected by neo-
mycin resistance after transfection with 8 Wg of DNA using the cal-
cium-phosphate precipitation procedure. The CHO stable clone ex-
pressing the PRLR/2L chimera was previously described [13].
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2.4. Cross-linking
Con£uent monolayer CHO cells (2U106) expressing the EPOR/2L
chimeric receptor were incubated with 1 nM 125I-labeled EPO with or
without 100-fold molar excess of unlabeled EPO in 1 ml of ligand
binding bu¡er (Ham’s F-12, 0.5% BSA, 0.1% azide) for 1 h at room
temperature. Cells were washed four times with PBS followed by
incubation with 0.5 mM disuccinimidyl suberate (DSS) for 15 min
at 20‡C. The cross-linking reaction was quenched by the addition of
50 mM Tris-HCl, pH 7.4. Cells were boiled in 50 Wl SDS sample
bu¡er and subjected to 7.5% SDS-PAGE prior autoradiography of
dried gel.
2.5. Cell labeling
CHO cells transfected with Kit/2L (106 cells) were immunostained
with ACK-2 antibody (10 Wg/ml) or with staining medium alone (PBS,
5% FCS, 0.2% azide) for 30 min at 4‡C. After washing, cells were
incubated with £uorescein-conjugated anti-rat IgG monoclonal anti-
body (1/10 dilution) for 30 min at 4‡C, washed and resuspended.
Fluorescence analysis was performed using a FACScan analyzer (Bec-
ton Dickinson, Grenoble, France).
2.6. Immunoprecipitation and Western blots
Cell lysates were immunoprecipitated with appropriate antibodies
(see Section 2.1); experimental procedures for immunoprecipitation,
electrophoresis and immunoblots were as described [13].
2.7. Transient transfection and luciferase assay
Transient transfection of stable clones with L-casein promoter-luci-
ferase reporter plasmid and L-galactosidase plasmid was performed as
described [13]. Transfected cells were incubated in serum-free medium
containing 250 nM dexamethasone and various concentration of
PRL, EPO or SCF for 48 h at 37‡C. Luciferase activity was measured
as previously reported [13] and values were normalized to the L-gal-
actosidase activity. Results are means þ S.E.M. from three independ-
ent experiments.
3. Results
3.1. Selection of stable clones
Although some data relating to the PRLR/2L chimeric re-
ceptor have been previously published [13], all the experiments
performed in the present study included the PRLR/2L clone
for direct comparison of the three chimeras within the same
experiments. Electrophoretic mobility of the 125I-EPO-EPOR/
2L cross-linked complex corresponded to a relative molecular
mass ofV104 kDa, in good agreement with the predicted size
of the chimeric receptor (68 kDa, including V10 kDa glyco-
sylation [17]) and the 35 kDa contribution of monomeric EPO
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Fig. 1. Schematic representation of native and chimeric receptors. Thin lines in the extracellular domain of PRLR, EPOR and IL-2RL indicate
cysteine residues and the black boxes the WSXWS motif; both motifs are conserved structural features among cytokine receptors [41]. Semi-
squares of the extracellular domain of Kit represent immunoglobulin-like structures. The hatched rectangle in the cytoplasmic domain symbol-
izes box 1, a proline-rich region highly conserved within the cytokine receptor superfamily. Kit contains a separated cytoplasmic tyrosine kinase
domain symbolized by two white rectangles.
Fig. 2. Identi¢cation of EPOR/2L and Kit/2L stable CHO clones. A: Autoradiography of EPOR/2L chimera cross-linked to 125I-labeled EPO in
stably transfected CHO cells. Binding was performed with (+) or without (3) excess unlabeled EPO. Numbers on the left indicate molecular
masses (kDa) of protein markers. The arrow on the right indicates the position of the EPOR/2L chimera-EPO complex. B: Flow cytometric
analysis of Kit/2L expression on CHO cells. CHO cells transfected with Kit/2L were immunostained with or without the rat antibody ACK-2,
speci¢c to the extracellular region of the murine Kit, followed by a secondary staining with £uorescein-conjugated anti-rat IgG antibody.
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(Fig. 2A). Band speci¢city was assessed by displacement of the
labeled complex with 100-fold molar excess of unlabeled EPO.
CHO clones expressing Kit/2L were selected by £ow cytome-
try and the integrity of the Kit/2L transfectant was con¢rmed
by a positive shift in £uorescence intensity (Fig. 2B).
3.2. Tyrosine phosphorylation of Jak2 and Stat5
Kit/2L and EPOR/2L chimeras were ¢rst tested for their
ability to induce Jak2 tyrosine phosphorylation. In the pres-
ence of the appropriate ligand (EPO, SCF or PRL, 10 min
stimulation), similar strong ligand-induced phosphorylation of
immunoprecipitated Jak2 was observed for the three clones
(Fig. 3A). Control immunoblot analysis revealed a similar
quantity of immunoprecipitated Jak2 for all conditions (Fig.
3B). We next investigated the ability of the chimeras to acti-
vate one of the known targets of Jak2, namely Stat5 tyrosine
phosphorylation [18]. Anti-phosphotyrosine immunoblot of
immunoprecipitated Stat5 showed a strong and similar li-
gand-dependent phosphotyrosine signal of Stat5 for the three
stable clones (Fig. 4A). Control anti-Stat5 immunoblot anal-
ysis revealed a comparable quantity of immunoprecipitated
Stat5 (Fig. 4B).
3.3. Transcriptional activation of L-casein reporter gene
Activation of the L-casein gene promoter is a known target
of the Jak2/Stat5 cascade [18]. For all chimeras, dose-depend-
ent activation of this construct was observed (Fig. 5). In
agreement with proliferation studies performed on lymphoid
cells transfected with Kit/2L or EPOR/2L, a maximal e¡ect
was achieved at concentrations of 200 ng SCF/ml [16] and
10 U EPO/ml [19], respectively. Higher EPO concentrations
did not result in any increase of the response (not shown).
Due to a limited supply, we could not assay higher doses of
SCF; however, the same induction observed at 100 ng/ml and
200 ng/ml (Fig. 5) indicates that these concentrations corre-
spond to the plateau of the response. Maximal activation of
PRLR/2L was achieved at PRL concentrations around 400 ng/
ml [13]. Transcriptional activation of the reporter gene was
similar for both PRLR/2L and EPOR/2L, with a maximal
induction around 8^10-fold. Kit/2L hybrid receptor was ap-
proximately two-fold less active, with a maximal luciferase
induction of 4^5-fold.
4. Discussion
Our previous observation that the PRLR/2L chimera is able
to mediate tyrosine phosphorylation of Jak2 was unexpected
[13], since the IL-2RL chain in the context of wild type IL-2R
recruits Jak1, and not Jak2 [12]. The aim of the present work
was thus to investigate whether this property might be due to
some speci¢c features intrinsically contained in the PRLR
extracellular domain, as previously suggested for the extrac-
ellular domain of other receptors [20]. As shown, substitution
of the EPOR extracellular domain for that of PRLR did not
alter the signaling properties of the IL-2RL chimeric receptor,
suggesting that parameters other than the intrinsic composi-
tion of the extracellular domain are involved in directing Jak2
activation by the IL-2RL cytoplasmic domain.
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Fig. 3. Tyrosine phosphorylation of Jak2. Serum-starved stable
CHO clones were stimulated (+) or not (3) with 400 ng PRL/ml,
10 U EPO/ml or 200 ng SCF/ml for 10 min. Cell extracts were im-
munoprecipitated with Jak2 antiserum and analyzed by anti-phos-
photyrosine (A) and anti-Jak2 (B) immunoblot. Numbers on the left
indicate molecular masses (kDa) of protein markers. The arrow on
the right indicates the position of Jak2.
Fig. 4. Tyrosine phosphorylation of Stat5. Serum-starved stable
CHO clones were stimulated (+) or not (3) with 400 ng PRL/ml,
10 U EPO/ml or 200 ng SCF/ml for 10 min. Cell extracts were im-
munoprecipitated with Stat5 antiserum and analyzed by anti-phos-
photyrosine (A) and anti-Stat5 (B) immunoblot. Numbers on the
left indicate molecular masses (kDa) of protein markers. The arrow
on the right indicates the position of Stat5.
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One major di¡erence between the wild type IL-2R and PRL
and EPO receptors is the stoichiometry of the activated com-
plexes. IL-2R is a heterotrimer, whereas PRL and EPO recep-
tors are homodimerized upon ligand binding [1]. Hence,
PRLR/2L and EPOR/2L are also assumed to homodimerize
after ligand binding to the extracellular region. In order to test
whether the receptor stoichiometry per se, in the present case
a homodimer, is su⁄cient to give IL-2RL the ability to acti-
vate Jak2, we analyzed the signaling properties of Kit/2L. Kit,
a member of the RTK family [21], does not signal through the
Jak/Stat pathways and like all RTKs is activated by ligand-
induced homodimerization [22]. Kit/2L exhibits a qualitatively
identical ability to stimulate Jak2 and Stat5 tyrosine phos-
phorylation compared to both other chimeras, strengthening
the observation that these properties are independent of the
intrinsic composition of the extracellular domain. Rather, this
indicates that the IL-2RL cytoplasmic domain intrinsically
possesses the ability to activate Jak2, but that this property
can only be displayed in a homodimerized complex.
Although the reduced transcriptional activity of Kit/2L
compared to the other chimeras was not investigated in detail,
one can postulate it is related to the overall structure of the
complexes. Indeed, crystallographic structures of genetically
engineered PRLR [23] and EPOR [24] extracellular domains
have shown that they are almost superimposable, suggesting
that homodimerized PRLR/2L and EPOR/2L complexes
adopt overall structures that are very similar to each other
as well as to wild type PRLR. The overall conformation of
Kit/2L, although still unknown, presumably markedly di¡ers
from that of cytokine receptors, since the Kit extracellular
domain is composed of ¢ve immunoglobulin-like domains
[21,22]. The conformation of homodimerized Kit/2L might
not allow optimal activation of the Jak/Stat signaling cascade
leading to L-casein transactivation. For instance, induction of
molecular event(s) other than tyrosine phosphorylation of
Jak2 and Stat5, such as serine phosphorylation of Stat5 [25^
27], might not be fully achieved by Kit/2L hybrid receptor.
Interestingly, SCF binding to Kit/2L expressed in D10 lym-
phoid cells did not induce detectable tyrosine phosphorylation
of cellular proteins, despite the presence of Jak kinases in
these cells [16]. This observation leads to the hypothesis that
the homodimerization step, the assumed prerequisite for sig-
nal transduction by this chimera, may not be su⁄cient to
activate phosphorylation pathways in some cell types, possibly
because other membrane components/features are also re-
quired. This underlines the importance of the cell type in
which experiments are carried out.
By merging receptor domains from two wild type receptors
that are both unable to activate Jak2 (Kit and IL-2RL), we
have generated an arti¢cial PRL-like receptor able to stimu-
late the Jak2/Stat5/L-casein cascade. In a general fashion, our
data suggest that the stoichiometry of a cytokine receptor
complex, and not only their intrinsic composition (i.e. the
type of subunits), can a¡ect their signaling properties and,
more particularly, that the homodimerization process of cyto-
kine receptor subunits plays a major role in providing the
ability to activate Jak2 (Table 1). Interestingly, all cytokine
receptors activated by homodimerization (GHR, PRLR,
EPOR, G-CSFR, Mpl) activate Jak2 [1,2,28]. Cytokine recep-
tors of the IL-3/IL-5/GM-CSF subfamily are also able to ac-
tivate Jak2, despite the fact that ligand-bound complexes are
formed by heterodimerization of the common Lc and a ligand-
speci¢c K chain. However, the K chains of these receptors
contain a box 1-like motif [29] whose deletion appears detri-
mental to signaling [30^33], including Jak2 tyrosine phospho-
rylation [34]. Although the K chain per se is not able to asso-
ciate with Jak2, Lc does [35], thus it is possible that
dimerization of the box 1(-like) motifs following ligand-in-
duced clustering of K and Lc subunits allows recruitment of
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Table 1
Summary of some functional characteristics of activated native and chimeric receptors
Functional characteristic Wild type receptors Chimeric receptors
Cytokine receptors RTK
PRLR EPOR IL-2R Kit PRLR/2L EPOR/2L Kit/2L
Stoichiometry homodimer homodimer heterotrimer homodimer homodimer homodimer homodimer
Jak2 tyrosine phosphorylation ++ ++ 3 3 ++ ++ ++
Stat5 tyrosine phosphorylation ++ ++ ++ 3 ++ ++ ++
L-Casein gene: DNA binding ++ ++ ++ ND ND ND ND
transactivation ++ 3 ND ND ++ ++ +
Reference [13] [42,43] [42] ND this study
++: strong activation; +: moderate activation; 3 : no activation; ND: not determined.
The table indicates the following parameters: stoichoimetry of ligand-bound receptors, tyrosine phosphorylation of Jak2, tyrosine phosphorylation
of Stat5 and activation of the L-casein gene promoter. For the latter, DNA binding in gel shift assay experiments and transactivation of a L-casein-
reporter construct are distinguished. The predicted stoichiometry of chimeric receptors is based on that of native receptors from which the
extracellular domain originates. Receptor homodimerization in the context of both wild type and hybrid receptors parallels the ability to activate
Jak2; Kit/2L displays reduced ability to induce L-casein gene transcription.
Fig. 5. Induction of the L-casein gene promoter. Stable CHO clones
expressing chimeric receptors were transiently transfected with L-ca-
sein-luciferase plasmid (see Section 2). Cells were stimulated with
various concentrations of PRL, EPO or SCF in the presence of 250
nM dexamethasone. The fold induction is calculated as described in
Section 2. Results represent the mean þ S.E.M. of three independent
experiments.
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a Jak kinase (Jak1 and Jak2) by each subunit, and further
activation by transphosphorylation. The gp130 subfamily
(LIF, OSM, CNTF and IL-6 receptors) also activates Jak2.
The three former complexes contain a L chain (gp130) and a Q
chain that both contain a box 1 motif able to interact with a
Jak protein. The IL-6R does not contain a Q chain, but acti-
vation of a signaling complex requires homodimerization of
the gp130 transducer, leading to clustering of two box 1 mo-
tifs [36,37]. Finally, IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15
are the only class 1 cytokine receptors that do not activate
Jak2. Remarkably, although the L chains of these receptors
contain a box 1 motif, which associates with Jak1, their Q
chain is devoid of box 1 motif and associates with Jak3
through the C-terminus of the cytoplasmic domain [12].
In conclusion, we postulate that the activation of Jak2 re-
quires the presence of two copies of box 1(-like) motifs, which
can be achieved by homodimerized receptors (EPOR, PRLR,
etc.) or by hetero-oligomerized receptors (IL-6R or IL-3R
subfamilies) involving subunits having box 1 motifs. The pres-
ence of two box 1 is not always su⁄cient for activating Jak2,
however, since heterodimerization of the short and intermedi-
ate PRLR isoforms, despite the fact that both contain a box 1
and activate Jak2 in homodimerized PRLR [38], leads to in-
active complexes [39,40]. This suggests that in some [39,40],
but not all [7] cases, the involvement of additional motifs
downstream of box 1 might also be involved or, alternatively,
that some degree of structural compatibility between clustered
subunits is required. Further studies on Jak-receptor interac-
tion will be required to better understand the molecular re-
quirements of these associations.
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